159 results about "Blood Vessel Endothelium" patented technology

A dual-layer bag catheter is composed of two ball layers and three cavities. Its internal bag layer is used for expanding blood vessel. Its external bag layer made of unique millipore film is used for delivering the therapeutic genes or medicine to the wall of blood vessel or target organ.

The invention relates to a method for preparing a biodegradable polymer self-expansion type intravascular stent based on 3D printing technology.The method includes the specific steps of synthesizing polylactic acid-based shape-memory polyurethane/Fe304 nanocomposite material with good biocompatibility and biodegradability, and making the composite material into the intravascular stent through the Fused Deposition Modeling technology.In addition, in order to increase the blood vessel endothelium repair speed, sirolimus, heparin, endothelial growth factors or the like are selectively introduced to the stent surface through electrostatic spinning.A 'time'dimension is added for the shape-memory function of the base material, and combined with the 3D printing technology, a 4D forming concept is given to the stent.By means of the magnetocaloric effect of Fe304, shape recovery of the shape-memory polymer can be remotely excited, so that the intravascular stent expands automatically, balloon dilatation is not required during stent implantation, axial shortening during balloon dilatation and radial resilience during withdraw of the stent are avoided, and damage of blood vessels is reduced to a minimum level.In addition, the introduction of Fe304 solves the problem that a polymer stent has poor development.

The invention discloses an interventional medial device comprising a balloon dilatation catheter body. A balloon on the balloon dilatation catheter body consists of a straightness section and conical sections positioned at two ends of the straightness section, wherein a medical coating is coated on the surface of the straightness section of the balloon and consists of medicaments and a medicine delivery promoting agent. When the balloon is used for dilating the narrow blood vessel, the medicament in the medical coating can be released rapidly, so that the injury of the endothelium of the blood vessel can be repaired, the hyperplasia of smooth muscle cells can be inhibited, the restenosis rate of the blood vessel can be reduced, and the endothelialization dysfunction possibly caused by the long-term continuous contact between the medical coating and the blood vessel wall can be avoided.

The invention relates to a novel magnetic molecular targeted ultrasound contrast agent, in particular to a gas-wrapped magnetic liposome microsphere suspension with the mean diameter of 1-4 micrometers and a preparation method thereof. The preparation method of the magnetic molecular targeted ultrasound contrast agent microsphere comprises a condition that a lipid layer of the microsphere and/or the surface of the lipid layer contains (or connects) magnetic response materials. A contrast agent microsphere wall material contains phospholipids, polyethylene glycol (PEG), PEG phospholipid polymers, biotinylated and/or polypeptide modificatory PEG phospholipid polymer, poloxamer, ligands (monoclonal antibodies or polypeptide, and the like) and the magnetic response materials and/or avidin bridging materials, wherein the ligand (monoclonal antibodies or polypeptide, and the like) has specific affinity to target molecules, the wrapped gas is a fluorine carbon gas, and a solvent is an aqueous medium (distilled water). The invention also provides the preparation method of the magnetic molecular targeted ultrasound contrast agent microsphere, which comprises a condition that the specific ligand is connected with the microsphere in a covalence and avidin bridging way. The novel magnetic molecular targeted ultrasound contrast agent has good targeted developing effect, can be used for evaluating the change of vessel endothelial molecules of an arterious and venous system of an organic tissue and has good application prospect in treatment.

Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. HUVEC cells, and methods of treating a subject in need thereof with such organoids. Further, the isolated renal cells, which may include tubular and erythropoietin {EPO}-producing kidney cell populations, and/or the endothelial cell populations may be of autologous, syngeneic, allogeneic or xenogeneic origin, or any combination thereof. Further provided are methods of treating a subject in need with the organoids.

The invention provides a nano-microcapsule coated intravascular stent of a core-shell structure and a preparation method of the nano-microcapsule coated intravascular stent, applicable to the technical field of medical instruments. Based on a coaxial electrostatic spraying technology which has characteristics of being efficient, simple and convenient, and having microspheres controlled to release and the like, a uniform nano-microcapsule coating is sprayed on a surface of a stent body part, namely the stent comprises a metal stent body part having an outer surface, having an excellent mechanical property; and a uniform drug coating, wherein the coating which is formed by uniformly depositing drug-loaded nano-microcapsules of core-shell structure, can encapsulate multiple drugs and has a good slow-release effect. The drug stent coating prepared by the invention is controllable in coating thickness, simple in preparation process, low in equipment requirement and high in preparation efficiency. Depending on curative effect of the required stent, variety of the encapsulated drugs, encapsulated drug dosage and encapsulation way can be changed to realize different release effects; and the intravascular stent is favorable for blood vessel endothelium repairing and inhibiting restenosis.

A method for regenerating a blood vessel comprising introducing a cell-containing fluid containing vascular endothelial precursor cells and cells to be removed into a cell separator which allows at least the cells to be removed to substantially pass through but substantially captures the vascular endothelial precursor cells; recovering the vascular endothelial precursor cells once captured on said cell separator by introducing a fluid into the said cell separator; and using the recovered vascular endothelial precursor cells for regenerating a blood vessel.

It is intended to provide a screening system for a centrally acting drug transported across the blood-brain barrier, a drug acting on the blood-brain barrier itself, or a drug transferred into the brain without being expected to centrally act. Moreover, another object of the present invention is to achieve pathogenesis analysis study or the screening in a diseased state by applying various diseased environments to this screening system. The present invention provides an in-vitro model of blood-brain barrier obtained by using a three-dimensional culture apparatus comprising: a culture solution; a plate holding the culture solution; and a filter immersed in the culture solution and placed in no contact with the inside bottom of the plate, the filter having plural pores of 0.35 to 0.45 μm in diameter, and by comprising: seeding primary cultured brain capillary endothelial cells onto the upper surface of the filter; seeding primary cultured brain pericytes onto the under surface of the filter; seeding primary cultured astrocytes onto the inside surface of the plate; and coculturing these cells in a normal culture solution.

The invention discloses an ultrasonic-cavitation-injury-based method for establishing an atherosclerotic-plaque animal model and a blood vessel endothelial injury device. The device comprises a composite probe, a B-mode image guiding module, a motion control module, a time sequence signal control and power drive module and a cavitation detection module. According to the invention, an endothelial ultrasonic-cavitation injury of a local artery blood vessel with controlled injury site, injured area, and injury degree can be realized; and then high-fat diet feeding is combined to form a method for establishing an atherosclerotic-plaque animal model with controllable and predictable plaque formation position and size. An atherosclerotic-plaque animal model for detecting imaging method sensitivity and effectiveness at different development stages can be established; no surgical operation is needed during the artery blood vessel endothelium injuring process; and the blood vessel endothelial injury difficulty and complexity are reduced.

The invention belongs to the field of pharmacy, and relates to applications of leonurine in preparation of medicines used for treating atherosclerosis. Leonurine possesses a structure represented by formula (I). It is shown by results of experiments on a rabbit model with high fat diet induced atherosclerosis that, leonurine possesses anti-inflammatory activity and antioxidant activity, so that leonurine is capable of increasing the content of high-density lipoprotein, reducing the content of total cholesterol, reducing mean blood flow velocity of arteries, improving blood flowing states, protecting the integrity of blood vessel endothelium, and reducing deposition of lipid in blood vessels and generation of macrophage, and can be used for treating atherosclerosis.

The invention discloses a method for preparing a mesoporous silicon nanoparticle coating loaded with heparin and Cu<2+> on the surface of a biological material. The method comprises the steps of carrying out surface modification on mesoporous silicon nanoparticles to obtain amino-modified mesoporous silicon nanoparticles to load heparin and Cu<2+> into a mesoporous duct; modifying the surfaces of the nanoparticles by using albumin; and finally fixing the nanoparticles on the surface of the dopamine-modified biological material to obtain the mesoporous silicon nanoparticle coating loaded with the heparin and the Cu<2+>. Surface modification is carried out on a material or device implanted into a blood vessel by adopting the method, so that the loading capacity and the release behavior of the heparin and the Cu<2+> on the surface of the material can be effectively controlled, the material is endowed with good blood compatibility and regeneration of blood vessel endothelium can be significantly promoted, thereby effectively improving the biocompatibility and the implant success rate of the material.

The invention discloses a method for establishing a domestic rabbit atherosclerosis model, wherein the method includes high-lipidation processing on a domestic rabbit basic feed and intravenous injection of bovine serum albumin, also includes combined use of a vagina vasorum and a forcemeter for making domestic rabbit artery blood vessel endothelium injured, and particularly includes the following steps: carrying out paracentesis on a middle-lower segment of a femoral artery by 21G radial artery puncture needles; after the paracentesis is successful, inserting into a radial artery sheathing canal with the depth of 5 cm with the help of a guide wire; followed by, carrying out intravenous injection of 200 U/kg of heparin at an ear edge; after pulling out the guide wire, fixing a fine line at the tail end of the vagina vasorum, making the other end of the fine line connected with the forcemeter, allowing fingers of a left hand of an operative doctor to draw close to each other and press a femoral artery part internally containing the vagina vasorum, allowing a right hand to hold the forcemeter to pull out the vagina vasorum to 4 cm, and allowing the left hand pressing force to be 10 N displayed in the forcemeter as a degree, so as to cause vascular endothelial injury. The invention aims to provide the modeling method for the domestic rabbit atherosclerosis model, wherein the modeling method is short in period, strong in operability and relatively low in cost.

The invention provides an endothelial cell culture medium and an endothelial cell culture method, wherein the endothelial cell culture medium comprises a serum-free basal culture medium, insulin, transferin, vitamin C, bovine serum albumin, a basic fibroblast growth factor, a blood vessel endothelium growth factor, a stem cell growth factor, laminin, an epidermal growth factor, non-essential amino acid and melbinum hydrochloride. By virtue of compatibility of ingredients, the endothelial cell culture medium provided by the invention is capable of improving the endothelial cell multiplication capacity. In addition, the endothelial cell culture medium provided by the invention is further capable of improving the blood vessel formation capability of endothelial cells. The experimental result indicates that when endothelial cells are cultured to the P10 generation by virtue of the endothelial cell culture medium provided by the invention, the cells still grow vigorously; the P10-generation endothelial cell phenotype CD309 and CD31 double-positive expression is as high as 97.2%.

The present invention relates to a medicine composition conlaining resulvatatine or pivatatine compound and vitamins B, in which the resulvatatine or pivatatine content is 1-40 mg and vitamins B content is 0.1-50 mg. Said invention also provides the application of said medicine composition in preparation of medicine for preventing and curing the diseases of atherosclerosis, angiocardiopathy and cerebrovascular disease.

The related chalketoxime shown as the formula (1) is prepared by heating and reflux reacting the 2', 4'-dihydroxy -6'-methoxyl-3', 5'-dimethylchalcone and hydroxylamine hydrochloride in pyridine, which has well solvability, fit to direct inject for drug, restrains obviously all of the activity of blood vessel endothelium growth factor receptor, HER2 receptor and Tyr kinase as PDGFR receptor, the external growth of cells for breast cancer and liver cancer, and the phosphorylation of KDR in ECV304 cell, HER2 in MDA-MB-453 cell and PDGFR receptor in C6 cell, and benefit to treat tumor.

The invention relates to model preparation, particularly to a rabbit portal vein thrombosis model which establishes a rabbit portal vein thrombosis model by a portal vein ligation catheterization method. The experimental animal adopts a New Zealand white rabbit; the experimental process comprises the steps of preoperative preparation: a preoperative experimental rabbit fasts all night and freely drinks water; anaesthetization; operation method: make the preoperative preparations including shaving feathers at the operating area after anaesthetization, disinfection and the like, enter the belly layer by layer, separate a portal vein, insert a 2Fr internal jugular vein tube by a catheterization method, ligate the portal vein using the tube as the inner support, suture and fix, lead to outside of body, and then conducting firm fixing. The model of the invention causes partial blood stasis, annular oppressed damage of blood vessel endothelium by ligating the portal vein, simultaneously carries out tube stimulation, starts intrinsic and extrinsic coagulation processes, increases the incidence of thromboembolism, and provides passages for the later partially collecting blood specimen, dynamic venogram, partial injection and the like; the first PVT occurrence time is about 30 min after the model is found via the portal vein radiography, and the model formation rate is higher than 75%.

The invention discloses an in-vitro construction method for simulating a blood brain barrier through human brain microangiogenesis. The method comprises the following steps: preparing human brain microvascular endothelial cell suspension and human astrocyte suspension, and preparing fibrinogen mother liquor and thrombin mother liquor; mixing the endothelial cell suspension, the astrocyte suspension, a DMEM (Dulbecco's Modified Eagle Medium) medium, the fibrinogen mother liquor and the thrombin mother liquor, and preparing a mixed cell gel solution; injecting the mixed cell gel solution into amicro-fluidic chip, performing thermostatic incubation to gelation, adding an endothelial growth medium into the micro-fluidic chip, and constructing a 3D cell culture chip; performing continuous culture on the 3D cell culture chip, and enabling the endothelial cells and astrocyte to grow into a brain microvascular network structure, namely correspondingly producing the simulated blood brain barrier. According to the technical scheme provided by the invention, the in-vitro model of the blood brain barrier is successfully constructed, and the characteristics of the blood brain barrier are clearly and accurately reflected.

The invention discloses a tissue engineering bionic liver lobe structure based on 3D printing of living cells and a preparation method thereof. Firstly, biological information of human body liver lobes is collected, and inputted into a computer for high biomimetic modeling; then, material separated printing and material-cell mixed printing output are performed with a hydrogel material and cells for constructing liver, bile duct epithelium, blood vessel endothelium, smooth muscle and fibroblast and the like required for the human liver lobes by a biological 3D printer, wherein a hollow part inblood vessels and bile ducts is printed by a casting agent; after all the hydrogel materials are solidified, the casting agent in the blood vessels and bile ducts are removed by means of enzymes or chelating reactions or temperature control or illumination and the like, and a vascular system and a bile duct system in the artificial bile duct-containing liver lobes are constructed. The circulationfeeding of the vascular system of the bionic liver lobes and gas exchange are achieved by connection of main blood vessels at two ends of the vascular system and a delivery pipe of a culture solution.The long-term survival and biological function of the bionic liver lobes in vitro and in vivo are achieved.

The invention discloses a cyclodextrin functionalized derivative carrier system based on polyamide-amine and its application. The carrier system is made of cyclodextrin functionalized with polyamide-amine. The chemical The structure is as follows: Among them, cyclodextrin is β-cyclodextrin or its derivatives, γ-cyclodextrin or its derivatives, PAMAM is the core of ethylenediamine, and the end is aminated polyamide-amine (G0-G4), m =2-6; the carrier system has the function of simultaneously loading tanshinone IIA drugs, and can jointly load drugs and genes; the carrier system can be applied to in vitro gene cell transfection and treatment of arterial restenosis; the present invention is aimed at According to the characteristics of endothelial injury, a new type of carrier system is proposed, which can simultaneously load tanshinone drugs and genes, which can effectively repair the damaged endothelium, inhibit the proliferation of tissue cells, and achieve the effect of synergistic treatment. It has a good application prospect in prevention and treatment.

The invention relates to a preparation for promoting revascularization or angiogenesis and a preparation method thereof. The preparation method of the preparation comprises the following steps of: inducing mononuclear cells to obtain endothelial progenitor cells (EPCs); then culturing the EPCs under the conditions of low blood serum and low oxygen; and finally separating the EPCs to obtain an acellular culture medium, and carrying out relevant aftertreatment on the acellular culture medium to obtain the preparation. The experiments in vitro and vivo indicate that the preparation for promoting revascularization or angiogenesis can obviously promote the regeneration of vessel tissues or the restoration of damaged vessel tissues.

The invention discloses a blood intra-cavity support which comprises a tubular support body. Through holes communicated with the inner side and the outer side are formed in the side wall of the support body. The hole axes of the through holes incline to the axial end of the support body. According to the blood intra-cavity support, the through holes communicated with the inner side and the outer side are formed in the side wall of the support body and the blood can be kept circulated inside and outside the support in a branch blood vessel; meanwhile, the hole axes of the through holes incline to the axial end of the support body, the blood intra-cavity support is placed in the mode that the inner ends of the through holes incline in the blood flow direction, the blood is prevented from directly impacting the blood vessel intima, the blood is promoted to flow in the support in a layered mode, vortexes are not generated in the through holes, damage caused by blood flow to the blood vessel intima is greatly reduced, and the blood vessel intima is well protected. Meanwhile, due to the fact that most of the blood vessel intima is not covered at the portion where the blood intra-cavity support is implanted, partial blood vessel endothelium still maintains the functions, interference caused by the support in the functions of the endothelium is reduced, and the good treatment effect is achieved.

The present invention relates to the application of 23-hyroxy betulic acid in inhibiting vascularization, and relates to Chinese medicine application technology. The present invention discloses the new use of 23-hyroxy betulic acid in inhibiting vascularization, and research shows that 23-hyroxy betulic acid has vascularization inhibiting effect. The effective dosage of 23-hyroxy betulic acid in preventing and treating medicine for inhibiting vascularization is 3-50 mg each kg of body weight each day. The present invention adopts vascularization as disease treating target, and has the advantages of specificity; direct action of medicine to blood vessel endothelial cell resulting in small dosage, high curative effect and less side effect; and less drug resistance.

The invention discloses a traditional Chinese drug for lowering lipid, improving effects and attenuating functions of statins drugs, which is prepared by raw materials according to the proportions as follows: 1000 portions to 3000 portions of star anise powder, 500 portions to 1000 portions of Seleniotatin red yeast rice and 0.01 portions to 0.05 portions of beta-cyclodextrin inclusion selenium. By the comprehensive action of active ingredients extracted from the star anise powder and Seleniotatin red yeast rice, and the beta-cyclodextrin inclusion selenium, the traditional Chinese drug has the lipid management function for controlling cholesterol synthesis, the function for healing and maintaining blood vessel endothelium so as to ensure youthful blood vessel as well as liver protection, spleen strengthening and stomach nourishing, the functions of eliminating free radicals and enhancing the immune function of organism and the like; the traditional Chinese drug has the functions of improving the functions of and attenuating the statins drugs and can solves the fundamental problems of the origins of cardiovascular and cerebrovascular diseases from many aspects without toxic and side effects, therefore the traditional Chinese drug can be used in a comparatively large dose for a comparatively long time, and a new choice is provided for the treatment of hyperlipemia and cardiovascular and cerebrovascular diseases caused by hyperlipemia and atherosclerosis as well as the control of the occurrence of cardiovascular and cerebrovascular events.

The invention relates to a medicament for curing coronary heart diseases. The medicament is a preparation which comprises the following crude drugs by the weight part: 8 to 16 parts of Chinese angelica root, 9 to 19 parts of hoantchy root, 9 to 18 parts of ligusticum wallichii, 9 to 18 parts of red-rooted salvia root, 8 to 16 parts of Chinese thorowax root, 9 to 18 parts of glossy privet fruit, 9 to 18 parts of scrophulariaceae canaria, 9 to 18 parts of eucommia bark, 3 to 6 parts of aloe and 4 to 8 parts of antifebrile dichroa. The formula of the medicament focuses on the regulation of kidney functions, and at the same time, attaches importance to the coordination of functions of internal organs, such as the kidney, the heart, the liver, the spleen, etc. The medicament can not only reduce blood lipid, resist coagulation, reduce blood viscidity and dissolve internal clot, but also improve the functions of blood vessel endothelium. Furthermore, the medicament can remove vasospasm, resist arteriosclerosis and stabilize vulnerable plaque, and have double curative effects on blood diseases and vascular diseases, thereby effectively curing the cardiovascular system diseases.

The invention discloses a genetic engineering protein-recombinant human fibroblast growth factor 21 capable of preventing and treating atherosclerosis and related diseases. The recombinant human FGF21 protein obtains patent protection by an applicant (the potential number: ZL200810223501.0). The recombinant human FGF21 protein is capable of effectively relieving and controlling pathogenesis of atherosclerosis by promoting external flow of fat in vascular endothelial cells and reducing accumulation of fat in blood vessel endothelium. Therefore, compared with other listed medicines, the recombinant human FGF21 protein has the advantage that prevention and treatment can be carried out with respect to the sources of atherosclerosis and a coronary heart disease. In addition, through analysis of a lot of clinical data, the inventor discovers that the FGF21 can be applied to auxiliary diagnosis of indexes of the atherosclerosis and the coronary heart disease, and has remarkable correlation in content increase in serum and morbidity of the coronary heart disease. In view of wide action of the recombinant human FGF21 protein in prevention, treatment and diagnosis of the atherosclerosis, the inventor believes that the clinical application value of the recombinant human fibroblast growth factor 21 is great.